Balance Sheet Components (Tables)
|
6 Months Ended |
12 Months Ended |
Jun. 30, 2025 |
Dec. 31, 2024 |
| Disclosure Of Balance Sheet Components [Abstract] |
|
|
| Summary of Prepaid Expenses and Other Current Assets |
Prepaid expenses and other current assets as of June 30, 2025 and December 31, 2024, consisted of the following (in thousands):
|
|
|
|
|
|
|
|
|
| |
|
June 30, 2025 |
|
|
December 31, 2024 |
|
Prepaid foreign consumption tax |
|
$ |
— |
|
|
$ |
81 |
|
Prepaid research and development costs |
|
|
6,362 |
|
|
|
57 |
|
Other receivables |
|
|
99 |
|
|
|
83 |
|
Prepaid other |
|
|
100 |
|
|
|
129 |
|
|
|
|
|
|
|
|
|
|
Prepaid expenses and other current assets |
|
$ |
6,561 |
|
|
$ |
350 |
|
|
|
|
|
|
|
|
|
|
|
Prepaid expenses and other current assets as of December 31, 2024 and 2023, consisted of the following (in thousands):
|
|
|
|
|
|
|
|
|
| |
|
|
|
| |
|
|
|
|
|
|
Prepaid foreign consumption tax |
|
$ |
81 |
|
|
$ |
98 |
|
Prepaid research and development costs |
|
|
57 |
|
|
|
— |
|
Other receivables |
|
|
83 |
|
|
|
223 |
|
Prepaid other |
|
|
129 |
|
|
|
106 |
|
|
|
|
|
|
|
|
|
|
Prepaid expenses and other current assets |
|
$ |
350 |
|
|
$ |
427 |
|
|
|
|
|
|
|
|
|
|
|
| Summary of Other Non-Current Assets |
Other non-current assets as of June 30, 2025 and December 31, 2024, consisted of the following (in thousands):
|
|
|
|
|
|
|
|
|
| |
|
June 30, 2025 |
|
|
December 31, 2024 |
|
Investment in Celexor |
|
$ |
942 |
|
|
$ |
942 |
|
|
|
|
69 |
|
|
|
69 |
|
Property and equipment, net |
|
|
3 |
|
|
|
8 |
|
|
|
|
|
|
|
|
|
|
|
|
$ |
1,014 |
|
|
$ |
1,019 |
|
|
Other non-current assets as of December 31, 2024 and 2023, consisted of the following (in thousands):
|
|
|
|
|
|
|
|
|
| |
|
|
|
| |
|
|
|
|
|
|
Deferred offering costs |
|
$ |
1,888 |
|
|
$ |
— |
|
|
|
|
69 |
|
|
|
123 |
|
Investment in Celexor |
|
|
942 |
|
|
|
942 |
|
|
|
|
|
|
|
|
|
|
|
|
$ |
2,899 |
|
|
$ |
1,065 |
|
|
|
|
|
|
|
|
|
|
|
| Summary of Accrued Expenses and Other Current Liabilities |
Accrued expenses and other current liabilities as of June 30, 2025 and December 31, 2024, consisted of the following (in thousands):
|
|
|
|
|
|
|
|
|
| |
|
June 30, 2025 |
|
|
December 31, 2024 |
|
Accrued research and development costs |
|
$ |
1,469 |
|
|
$ |
654 |
|
Accrued compensation |
|
|
480 |
|
|
|
931 |
|
Accrued professional fees |
|
|
88 |
|
|
|
485 |
|
Accrued financing cost |
|
|
2,258 |
|
|
|
1,294 |
|
Accrued other |
|
|
117 |
|
|
|
96 |
|
|
|
|
|
|
|
|
|
|
Accrued expenses and other current liabilities |
|
$ |
4,412 |
|
|
$ |
3,460 |
|
|
|
|
|
|
|
|
|
|
|
Accrued expenses and other current liabilities as of December 31, 2024 and 2023, consisted of the following (in thousands):
|
|
|
|
|
|
|
|
|
| |
|
|
|
| |
|
|
|
|
|
|
Accrued research and development costs |
|
$ |
654 |
|
|
$ |
785 |
|
Accrued compensation |
|
|
931 |
|
|
|
1,006 |
|
Accrued professional fees |
|
|
485 |
|
|
|
322 |
|
Accrued financing cost |
|
|
1,294 |
|
|
|
— |
|
Accrued other |
|
|
96 |
|
|
|
880 |
|
Foreign consumption tax payable |
|
|
— |
|
|
|
137 |
|
|
|
|
|
|
|
|
|
|
Accrued expenses and other current liabilities |
|
$ |
3,460 |
|
|
$ |
3,130 |
|
|
|
|
|
|
|
|
|
|
|